BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200831
DTEND;VALUE=DATE:20200903
DTSTAMP:20260515T113625
CREATED:20200703T082824Z
LAST-MODIFIED:20200703T082824Z
UID:26146-1598832000-1599091199@www.pharmajournalist.com
SUMMARY:Blood-Brain Barrier (BBB) Summit
DESCRIPTION:Going digital in its 2nd year\, the Blood-Brain Barrier (BBB) Summit is the industry’s definitive BBB conference focused on sharing the latest scientific advances\, data and key lessons learned for transporting more drugs across the BBB. \nWith a heavy focus on biologics\, for neurodegenerative diseases\, this summit will discuss topics such as quantitative methodologies for measuring amount and distribution of antibodies in the brain\, using PKPD systems to improve translation and predict clinical outcomes and importantly\, progress in the validation of approaches and technologies which enhance BBB transition. \nMoreover\, this meeting also aims to deepen your understanding of intracellular trafficking and receptor binding\, pharmacokinetics and protein engineering to drive the clinical applicability of receptor mediated transcytosis. The 2nd BBB Summit delves into identifying gaps in the physiology of the BBB and questions the extent of the relationship between the BBB and different disease states in various neurodegenerative diseases as well as uncovering what makes neural exosomes efficient BBB drug delivery tools. \nJoin fellow BBB specialists virtually to scrutinize progress of existing approaches to deliver more of your biologic therapeutic across the BBB to develop a clinically defining neurodegenerative treatment. \nTake a look at the full event guide here.
URL:https://www.pharmajournalist.com/event/blood-brain-barrier-bbb-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200903
DTEND;VALUE=DATE:20200905
DTSTAMP:20260515T113625
CREATED:20190926T131642Z
LAST-MODIFIED:20200317T131504Z
UID:22566-1599091200-1599263999@www.pharmajournalist.com
SUMMARY:ProcureCon Pharma 2020
DESCRIPTION:Taking place on 3 – 4 September 2020 in Berlin\, ProcureCon Pharma is your only opportunity to benchmark with the leaders of pharma procurement. \nJoin 120+ senior procurement professionals from Merck\, Astra Zeneca\, Roche\, Sanofi\, Lonza and other world leading Pharma businesses over 2 days and 40 interactive sessions that will help you make better outsourcing decisions\, speed up transformation\, co-create value with business partners and unlock more innovation from suppliers. To learn more about ProcureCon Pharma\, download the agenda. \nTake away answers to all of your top challenges: \n\nDeliver on and communicate value-added procurement activities to increase credibility as a business partner\nIdentify and adopt eProcurement technologies to modernize procurement\nMove from buyers and sellers to long-term strategic partners through SRM and Supplier-Led Innovation\n\nFor more information including the incredible speaker line-up\, download the agenda here:  http://bit.ly/2mnKKSw \nBook your place online today: http://bit.ly/2kR13a2  and get 15% off the current ticket price with our exclusive discount code – “PJOURNALIST20”
URL:https://www.pharmajournalist.com/event/procurecon-pharma-2020/
LOCATION:HOTEL PALACE BERLIN\, Germany
ORGANIZER;CN="Worldwide Business Research":MAILTO:ellie.boynett@wbr.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200908
DTEND;VALUE=DATE:20200909
DTSTAMP:20260515T113625
CREATED:20200908T095405Z
LAST-MODIFIED:20200908T095405Z
UID:26947-1599523200-1599609599@www.pharmajournalist.com
SUMMARY:Glioblastoma Drug Development Summit
DESCRIPTION:After an exceptionally successful inaugural launch last year\, the 2nd Annual Glioblastoma Drug Development Summit returns this year in an exclusive virtual format. \nGBM Drug Development is the only devoted meeting for large pharma\, biotech and pioneering academics which guarantees to unite all stakeholders under a mutual and ambitious objective of accelerating the practical discovery\, translation\, and clinical development of safe\, effective and deliverable therapies to treat glioblastoma\, an extremely aggressive cancer with a huge medical unmet need. \n \nConfronting specific and applied drug development obstacles with inadequate successful treatments\, such as the knowledge of glioblastoma’s mechanisms of resistance and lack of penetration via the blood brain barrier\, the 2nd Glioblastoma Drug Development Summit will help neuro-oncologists\, neurosurgeons  and oncology professionals from biopharma effectively translate their drug candidates into human clinical trials\, whilst optimizing the clinical development process itself to evade further clinical failures. \n\nBrought direct to your home office with a jam-packed agenda and online virtual networking opportunities\, this exclusive virtual summit will delve into the common challenges with developing GBM therapies\, whilst striving to advance safe and effective therapeutic breakthroughs to patients in need. \n\nTo know more about Glioblastoma Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/glioblastoma-drug-development-summit/
LOCATION:Online
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200916
DTSTAMP:20260515T113625
CREATED:20200415T103418Z
LAST-MODIFIED:20200724T145350Z
UID:25038-1600041600-1600214399@www.pharmajournalist.com
SUMMARY:Pre-filled Syringes San Francisco
DESCRIPTION:SMi is proud to announce the inaugural Prefilled Syringes San Francisco event taking place in September 2020. \nThe global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry\, is expected to exceed $9.7 billion by 2025. With that in mind\, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation\, new digital technology trends\, human studies and innovative design and delivery systems within the prefilled syringe industry. \n \nAs part of SMi’s leading Injectable conference series\, we will assess digital health and connected devices\, biologics\, biosimilars and biocompatibility for drug device combination products\, platform and device selection\, regulatory insights and explore the West Coast’s biotech innovators. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Device Testing Managers\, Senior Device Engineers\, Heads of Device Development\, Heads of Formulation and Drug Process Development\, and many more. \nPlus\, a workshop on human factors and risk management: \n\nIntegration of Human Factors Engineering processes in risk management saves time and money in product development\nEffective identification of use-related risk helps inform constructive design decisions\nMitigation of use-related risk improves treatment outcomes for end users\nUnderstanding the methods used to assess use-related risk will improve the efficiency and acumen of your organization\n\nBenefits of attending: \n\nEXPLORE the latest industry case studies in platform approaches and connected devices\nGAIN insights from leading industry and regulatory experts on the pre-filled syringes environment\nHEAR from local biotechs of San Francisco and the West Coast to learn about new innovations in the pre-filled syringes space\nENGAGE in the key challenges and topics of the field in two interactive half-day workshops\n\nChairs for 2020: \n\nShannon Clark\, Principal\, UserWise\nSteven Badelt\, Founder and Managing Partner\, Suttons Creek\, Inc.\n\nFeatured 2020 speakers include: \n\nKristina Lauritsen\, Combination Products Regulatory Advisor\, FDA/CDER\nManuela Gazzard\, Group Executive Director Regulatory Services Healthcare\, BSI\nChristine Lynn Lanning\, Distinguished Scientist\, Device Area Leader\, Safety Assessment/Merck & Co.\, Inc\nKhaudeja Bano\, Senior Medical Director\, Abbott Laboratories\nJace Blackburn\, Smart Device Engineer\, Genentech\nMichael Koby\, Senior Principle Scientist\, Pfi zer\nJames Leamon\, Director of Biologics Device Development\, Jazz Pharmaceuticals\nWalter Goodwin\, Device Engineer\, Device Development & Clinical Packaging Engineering\, Gilead Sciences\nKatie Atkinson\, Manager Human Factors Engineering\, Bigfoot Biomedical\n\n\nEARLY-BIRD RATES: \n\nBOOK BY 30TH APRIL AND SAVE £600\nBOOK BY 29TH MAY AND SAVE £300\nBOOK BY 30TH JUNE AND SAVE £200\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: #smipfsusa
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-san-francisco/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200916
DTSTAMP:20260515T113625
CREATED:20200415T104121Z
LAST-MODIFIED:20200416T132625Z
UID:25043-1600041600-1600214399@www.pharmajournalist.com
SUMMARY:Future Pharma 2020
DESCRIPTION:Future Pharma\nSeptember 14 – 15\, 2020\nBoston Marriott Long Wharf\, Boston\, MA\nwww.pharmaforce.wbresearch.com \n \nFuture Pharma is a two-day event that brings together heads of brands and franchises\, marketing\, sales and digital executives from leading pharmaceutical companies in an interactive and energizing setting. It is the only conference designed to help commercial leadership evaluate their personal and non- personal promotions\, align marketing and sales strategies and provide insight on commercial success in a post-pandemic industry landscape. \nWith limited vendor attendance and presentations\, you’ll experience true pharma-to-pharma networking in an interactive format. And by selecting sessions based on the topics you care about most\, you’ll connect with other marketing and sales executives who are focused on having the same\, critical conversations. \nFor more information on Future Pharma 2020\, download the agenda: bit.ly/2Vt69aL \nRegister now and SAVE 25% on your conference pass using our exclusive discount code FP20PJ: https://pharmaforce.wbresearch.com/srspricing
URL:https://www.pharmajournalist.com/event/future-pharma-2020/
LOCATION:Boston Marriott Long Wharf\, 296 State Street\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Worldwide Business Research":MAILTO:futurepharma@wbresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200917
DTSTAMP:20260515T113625
CREATED:20200629T075629Z
LAST-MODIFIED:20200629T075915Z
UID:26114-1600041600-1600300799@www.pharmajournalist.com
SUMMARY:2nd Annual RAS – Targeted Drug Development – Digital Summit
DESCRIPTION:Via the latest data driven case studies from academic and industry pioneers\, the 2nd RAS Targeted Drug Development Summit (running digitally this year!) will shine a spotlight on optimizing the selectivity and tolerability of your anti-RAS therapies\, exploring novel combination strategies and overcome translational pharmacology challenges to set the stage for the 2nd generation of mutation-targeted RAS modulating therapies yet to come. \n \n\nExplore how to leverage the internal structural biology of RAS mutations in order to produce effective and clinically viable therapies with discussions from E Shaw Research\, The Johns Hopkins University School of Medicine & Hospital for Sick Children\nDeep dive into RAS associated pathways in order to optimize combination therapies with insights from Novartis\, Genentech & Deciphera Oncology\nEvaluate the mechanisms of action and resistance of RAS targets to accelerate target validation and clinical translation with insights fromAbbvie\, PhoreMost & Verastem Oncology\nAdopt novel techniques to successfully target therapeutic vulnerabilities in RAS-driven cancers with lessons learnt from BeiGene\, Genentech\, Revolution Medicines\, Oblique Therapeutics & Aro Biotherapeutics\nExplore the successes and future therapeutic potential of targeting mutation beyond G12C from within the RAS community explored Revolution Medicines\, Francis Crick Institute & MD Anderson Cancer Centre\n\nFollowing the success of RAS-Targeted Drug Discovery Summit in 2019\, we will re-unite the RAS community virtually this coming September with the most comprehensive and definitive conference specifically dedicated to this community. \nJoin 250+ of the leading minds from large pharma\, biotech and academia across the globe who are striving to capitalise on the therapeutic opportunity of targeting RAS through advancing novel mechanisms of action\, improving drug-like properties and accelerating the translation of potent and mutation-targeted 2nd generation RAS targeted therapeutic strategies into human clinical trials.
URL:https://www.pharmajournalist.com/event/2nd-annual-ras-targeted-drug-development-digital-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200915
DTEND;VALUE=DATE:20200919
DTSTAMP:20260515T113625
CREATED:20200818T091000Z
LAST-MODIFIED:20200818T091220Z
UID:26798-1600128000-1600473599@www.pharmajournalist.com
SUMMARY:TIDES: Oligonucleotide & Peptide Therapeutics 2020
DESCRIPTION:The #1 event for oligonucleotide\, peptide\, CRISPR and mRNA therapeutic leaders. Join us for top-notch networking\, high-level industry expert speakers\, innovative company presentations\, interactive scientific poster presentations\, and diverse attendee companies and investors — in a multi-day digital format that you can access from anywhere in the world.
URL:https://www.pharmajournalist.com/event/tides-oligonucleotide-peptide-therapeutics-2020/
LOCATION:100% Virtual
ORGANIZER;CN="Informa Connect":MAILTO:Allison.MacDonald@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200922
DTEND;VALUE=DATE:20200925
DTSTAMP:20260515T113625
CREATED:20200615T080459Z
LAST-MODIFIED:20200615T080459Z
UID:25926-1600732800-1600991999@www.pharmajournalist.com
SUMMARY:11th World Bispecific Summit – Running Virtually for 2020
DESCRIPTION:Transforming to a digital platform for the eleventh year\, the World Bispecific Summit will continue to deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational and manufacturing challenges faced in the bispecific field. Whatever your role and interest in the field\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 40+ expert speakers are\, and the topics they will examine\, including how: \n\nMacroGenics are evaluating selection and format optimization of bispecific molecules for a simultaneous blockade of PD-1 and LAG-3 (MGD013) versus PD-1 and CTLA4 (MGD019)\nSound Biologics are pioneering their unique platform\, MabPair Technology for making bi-functional antibody\nInvenra demonstrates preclinical efficacy through the selective elimination of tumor Tregs\nIncyte and Adimab are enhancing the selectivity of bispecific approaches to reduce on-target off-tumor toxicities in solid tumor indications\nGenentech are showcasing how several factors such as epitope\, binding affinity\, format\, target expression\, etc.\, influence the design and development of T-cell bispecific for cancer immunotherapy\n\nDownload the event guide to find out more
URL:https://www.pharmajournalist.com/event/11th-world-bispecific-summit-running-virtually-for-2020/
LOCATION:Virtual Summit
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200924
DTEND;VALUE=DATE:20200925
DTSTAMP:20260515T113625
CREATED:20200716T140226Z
LAST-MODIFIED:20200716T140226Z
UID:26355-1600905600-1600991999@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium-1/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200928
DTEND;VALUE=DATE:20200930
DTSTAMP:20260515T113625
CREATED:20200217T113517Z
LAST-MODIFIED:20200817T084802Z
UID:24213-1601251200-1601423999@www.pharmajournalist.com
SUMMARY:2nd European Protein Degradation Congress
DESCRIPTION:With deals in the protein degradation market reaching nearly $2 billion and unique degradation ideas coming into play such as LYTACs and ENDTACs\, eyes are focused on how much further protein degradation-based therapeutics will continue to grow within the pharmaceutical industry. \nFollowing huge success in May 2019\, the 2nd European Protein Degradation Congress\, returns on 28th – 29th September 2020\, where you can hear the most up to date and relevant information for the broad range of topics in the field of targeted protein degradation. \n \nNew areas will cover novel methods in harnessing E3 ligases and the latest discoveries from PROTACs and molecular glues with preclinical and clinical data being shown. \nLeading industry players from biotechs and big pharma will come together to exchange thoughts on how to best overcome obstacles to achieving reliable in vitro and in vivo data. Academic experts will be present their latest research to help build a deeper understanding of the mechanisms involved in the Ubiquitin pathway\, providing a clearer picture on what makes a good\, or not good\, target for degradation. \nTo know more about 2nd European Protein Degradation Congress please click here.
URL:https://www.pharmajournalist.com/event/2nd-european-protein-degradation-congress/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201001
DTSTAMP:20260515T113625
CREATED:20200715T141216Z
LAST-MODIFIED:20200715T141216Z
UID:26338-1601424000-1601510399@www.pharmajournalist.com
SUMMARY:Gene Therapy for Inherited Metabolic Disorders
DESCRIPTION:The inaugural Gene Therapy for Inherited Metabolic Disorders Summit will put the spotlight on the understanding of topics from the physiopathology of disease through to the nuances of dosing and delivery methods and designing a trial with endpoints and outcome measures that are meaningful both clinically and to patients. \n \nJoin 60+ industry leaders across the metabolic disorders space to overcome the specific delivery and drug development challenges to accelerate the development of more clinically efficacious\, durable and safe gene therapies for metabolic disorders. \nDon’t miss this opportunity to join pioneers from AstraZeneca\, Amicus Therapeutics and Rocket Pharmaceuticals on this journey to revolutionize the treatment of inherited metabolic disorders. \nTo know more about Gene Therapy for Inherited Metabolic Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-inherited-metabolic-disorders/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201001
DTSTAMP:20260515T113625
CREATED:20200720T141737Z
LAST-MODIFIED:20200720T141737Z
UID:26425-1601424000-1601510399@www.pharmajournalist.com
SUMMARY:Gamma Delta T Therapies Summit
DESCRIPTION:Accelerating the Development of Gamma Delta T Therapies in Oncology \nJoin us on Wednesday\, September 30\, to discuss the precise mechanisms of γδT cells\, examine donor selection for allogeneic therapies\, and deliberate the targeting of solid tumours. \nAs we virtually gather world-leading researchers at the Gamma Delta T Therapies Summit\, learn how the industry is effectively manipulating and engineering gamma delta cells with antibody and cell-based approaches for improved safety\, efficacy and manufacturability to bring to market effective Gamma Delta Therapies for patients in need. \nWith a unique opportunity to pose questions to experts and gain fresh insights on such a fast paced and growing field in a live Q&A\, this digital event is not to be missed. \nFind out more about the event and to see participation opportunities: https://ter.li/qk6gc1
URL:https://www.pharmajournalist.com/event/gamma-delta-t-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201002
DTSTAMP:20260515T113625
CREATED:20200821T150023Z
LAST-MODIFIED:20200821T150023Z
UID:26815-1601424000-1601596799@www.pharmajournalist.com
SUMMARY:5th Annual PREDiCT: 3D Oncology & Tissue Models
DESCRIPTION:The Digital 5th PREDiCT: 3D Oncology & Tissue Models Summit will return this September\, with defined tracks and a fresh speaker line-up\, bringing together preclinical scientists to discuss adoption and commercialization of 3D models as an integral part of drug development study. \nThis event is completely free for Drug Developers\, Researchers and Academics. To register your complimentary pass\, simply follow this link: www.3d-oncology-tissuemodels.com/take-part/register/. \nThis fully online meeting will feature over 30+ senior Preclinical Scientists from oncology to cardiovascular to musculoskeletal and CNS backgrounds\, to share their latest data and lessons learned from clinically translatable 3D models to disease modeling of mechanisms\, to attempting complex multi-cellular/organ systems to boost our understanding of functionality and physiological relevancy. \nEmbark on the 3D trailblazing community to boost your confidence in 3D models and accelerate bench to bedside drug development to provide a truly safe\, and effective treatment for patients! \nAccess your copy of the Full Event Guide here.
URL:https://www.pharmajournalist.com/event/5th-annual-predict-3d-oncology-tissue-models/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR